Cannabis Law Report

JANUARY 4, 2022

–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. Virpax”), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H.C. About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

Pharmaceutical 52

Pharmaceutical Research and Development Chronic Pain Events 52

MMJ Recs

APRIL 1, 2024

From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions. Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

MMJ Recs

NOVEMBER 20, 2023

Both THC and CBD have demonstrated analgesic properties, making them valuable for managing chronic pain conditions such as arthritis, fibromyalgia, and cancer-related pain. This breakthrough has provided new hope to patients with severe forms of epilepsy who had previously found little relief from conventional treatments.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. We believe that the new data we are revealing today is an extraordinary achievement in the field of pharmaceutical cannabinoids,” said Adam Kaplin, M.D.,

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

MMJ Recs

FEBRUARY 18, 2024

These may include chronic pain, nausea and vomiting related to chemotherapy, muscle spasms, seizures, and mental health disorders. One of the most well-known applications is pain relief, particularly for chronic pain, arthritis, and neuropathic pain.

Chronic Pain 52

Chronic Pain Marijuana Epilepsy Research and Development 52

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 5, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

NOVEMBER 15, 2021

–(BUSINESS WIRE)– #earnings — Virpax ® Pharmaceuticals, Inc. We continue to enhance our product pipeline, and because of our unique delivery technologies we have expanded our targeted indications beyond pain to include Central Nervous System (CNS) disorders and anti-viral indications. “Our

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Veriheal

FEBRUARY 21, 2023

According to the study, individuals living in states where medical cannabis is difficult to access are more likely to resort to prescription drugs to treat chronic pain or other debilitating conditions.

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

SEPTEMBER 20, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. About Virpax Pharmaceuticals.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

MAY 9, 2022

The company is following in the footsteps of GW Pharmaceuticals, a trailblazer that developed the first cannabis-based medicine to be licensed in the UK in 2010, Sativex for multiple sclerosis, which costs about £2,000 a year. However, NHS prescribing of the mouth spray remains very limited and varies across the country.

Chronic Pain 52

Chronic Pain Epilepsy Oil Pharmaceutical 52

LifeCannMD

NOVEMBER 24, 2023

Medical marijuana may be recommended for conditions such as chronic pain, epilepsy, multiple sclerosis, Crohn’s disease, cancer, and other qualifying conditions. Medical marijuana is known for its potential to alleviate symptoms like pain, nausea, muscle spasms, and seizures.

Marijuana 52

Marijuana Chronic Pain Conditions Patients 52

Cannabis Law Report

DECEMBER 29, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

NOVEMBER 18, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

JANUARY 18, 2022

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. About Virpax Pharmaceuticals. Virpax is developing branded product candidates for non-addictive pain management and neurological disorders using its proprietary technologies to optimize and target drug delivery. BERWYN, Pa.–(BUSINESS

Safety 52

Safety Chronic Pain Research and Development Pharmaceutical 52

Cannabis Law Report

JUNE 7, 2019

The farm is run by GW Pharmaceuticals, where around two million cannabis plants have been produced since its opening in 1998. Those suffering from epilepsy, nausea and chronic pain due to chemotherapy are now given the option to get the drug on prescription, reports The Mirror . Kent Live Report.

Chronic Pain 40

Chronic Pain Epilepsy Legalization Pharmaceutical 40

Veriheal

AUGUST 9, 2023

CBD, Trema micrantha, and the Study’s Significance CBD means cannabidiol , one of over a hundred compounds in the cannabis plant, and is widely celebrated as a potential treatment for a long list of health concerns, including chronic pain , epilepsy , i nsomnia , anxiety , and skin allergy.

CBD 96

CBD Cannabinoids THC Extraction 96

The Cannigma

JUNE 25, 2022

Patients must have a doctor’s prescription as well as permission from a regional pharmaceutical inspector to obtain cannabis products. Qualifying conditions include chronic pain, multiple sclerosis, spasticity, chemo-induced nausea, and treatment-resistant epilepsy. Poland’s medical cannabis program.

Legalization 112

Legalization Supply Chain Chronic Pain Tincture 112

Cannabis Law Report

SEPTEMBER 28, 2021

However, it is a whole different story if someone suffers from serious and chronic pain. In most situations, it is related to another chronic condition that cannot be cured quickly or at all. In this case, the patient needs to look for the best ways to treat pain and improve their life quality. Acupuncture. CBD Products.

Treatment 52

Treatment Chronic Pain Therapy Tincture 52

PrestoDoctor

OCTOBER 13, 2023

Marinol, also known as Dronabinol, is a medication used to treat a variety of conditions, including nausea and vomiting caused by chemotherapy, loss of appetite and weight loss in people with HIV/AIDS, as well as chronic pain. However, unlike marijuana, Marinol is a FDA-approved pharmaceutical drug.

THC 98

THC Chronic Pain Treatment Conditions 98

Veriheal

MAY 31, 2022

With a worsening opioid situation and an emerging acceptance of medical cannabis, the Lone Star State has a unique opportunity to develop a successful medical marijuana (MMJ) program for its millions of residents battling chronic pain and numerous other conditions. A Better Alternative for Chronic Pain.

Programs 52

Programs Chronic Pain Treatment Conditions 52

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. Medical marijuana products are produced and sold in Virginia by businesses called “pharmaceutical processors”. You can obtain medical marijuana in Virginia at one of the state’s five licensed pharmaceutical processors.

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

Cannabis Law Report

NOVEMBER 23, 2021

The products to be manufactured at the facility aren’t specified, but will be used for managing chronic pain, epilepsy, multiple sclerosis, and pain associated with palliative care. The subject land is zoned RU1 Primary Production. Further information on the proposed project can be found here.

Chronic Pain 52

Chronic Pain Epilepsy Environment Pharmaceutical 52

United Patients Group

APRIL 18, 2023

Because they often combine it with other drugs like cocaine or heroin or even legal ‘prescribed’ pharmaceuticals–and those are far more dangerous than cannabis itself! For example, if you have chronic pain and want relief from muscle spasms and stiffness in your joints, then an indica strain may be best for you.

Research and Development 116

Research and Development Indica Treatment Conditions 116

Cannabis Law Report

JANUARY 3, 2022

TASE: PNAX), a global pharma company that develops, manufactures and markets progressive cannabis-based products in pharmaceutical quality, announced today that it has received official approval for the EU-GMP standard for its production facility in Malta from EU Health Authority. SOURCE Panaxia Pharmaceutical Industries.

Pharmaceutical 52

Pharmaceutical Chronic Pain Extraction Epilepsy 52

Veriheal

JANUARY 12, 2023

The law also permits the agricultural production of cannabis and hemp for industrial purposes, with a heavy emphasis on pharmaceutical crops. . Approximately 3,000 patients who suffer from debilitating conditions like chronic pain and epilepsy will partake in the project, which is due to end in March 2023.

Medicine 97

Medicine Chronic Pain Consumption Cannabis 97

MMJ Recs

JANUARY 6, 2024

Topicals , in the form of creams, balms, or patches, target localized pain or inflammation without inducing psychoactive effects. Capsules and pills provide a familiar oral ingestion method, akin to traditional pharmaceuticals. Cannabis oils can be consumed orally, added to food, or used in various ways, offering flexibility in dosing.

Chronic Pain 52

Chronic Pain Topical Marijuana Indica 52

United Patients Group

FEBRUARY 2, 2023

The ECS has been studied for its role in many diseases including cancer , epilepsy, chronic pain and multiple sclerosis (MS). For example, if your insomnia is due to pain or anxiety, cannabis can help you get some restful sleep. antibiotics).

Blood Pressure 105

Blood Pressure Sleep Chronic Pain Digestion 105

Medicinal Marijuana Association

JANUARY 19, 2019

Many experts believe that cannabis is a safe alternative to pharmaceuticals for relieving symptoms related to many illnesses. The properties in marijuana can greatly relieve chronic pain associated with these illnesses. It’s Safer than Pharmaceuticals. Medical marijuana is surrounded by controversy.

Legalization 75

Legalization Pharmaceutical Chronic Pain Patients 75

Cannabis Law Report

MARCH 25, 2020

Panaxia’s CBD-rich oil is targeted at specific group of patients that require a miniscule dose of THC (categories C20, C24) among whom is a large group of children suffering from epilepsy or autism spectrum disorder (ASD). About Panaxia Israel. Panaxia was founded by Dr. Dadi Segal , Dr. Eran Goldberg and Assi Rotbart , LL.b,

Oil 45

Oil Pharmaceutical Epilepsy Extraction 45

Veriheal

MAY 17, 2021

Please don’t further the lie by voting for any form of legalization beyond the pharmaceutical remedies already available under state law.” That is perhaps the biggest lie that is being perpetuated on the Alabama public today. ” State Doctors Oppose Legalization in Alabama.

Legalization 93

Legalization Pharmaceutical Therapy Chronic Pain 93

Veriheal

NOVEMBER 10, 2020

The experiment will allow participating companies to import cannabis and the companies who wish to participate in the experiment will be obliged to give participants free medical cannabis which has to comply with the pharmaceutical standards and good manufacturing practice. .

Chronic Pain 87

Chronic Pain Pharmaceutical Patients Epilepsy 87